137 related articles for article (PubMed ID: 23703399)
1. Intra-arterial tissue plasminogen activator and abciximab in patients with acute basilar artery occlusion.
Chiti A; Gialdini G; Terni E; Giannini N; Gennaro M; Lazzarotti GA; Puglioli M; Orlandi G; Bonuccelli U
Neurol Sci; 2013 Oct; 34(10):1871-3. PubMed ID: 23703399
[TBL] [Abstract][Full Text] [Related]
2. Acute basilar artery occlusion treated with combined intravenous Abciximab and intra-arterial tissue plasminogen activator: report of 3 cases.
Eckert B; Koch C; Thomalla G; Roether J; Zeumer H
Stroke; 2002 May; 33(5):1424-7. PubMed ID: 11988626
[TBL] [Abstract][Full Text] [Related]
3. Therapy of acute basilar artery occlusion: intraarterial thrombolysis alone vs bridging therapy.
Nagel S; Schellinger PD; Hartmann M; Juettler E; Huttner HB; Ringleb P; Schwab S; Köhrmann M
Stroke; 2009 Jan; 40(1):140-6. PubMed ID: 18927446
[TBL] [Abstract][Full Text] [Related]
4. Aggressive therapy with intravenous abciximab and intra-arterial rtPA and additional PTA/stenting improves clinical outcome in acute vertebrobasilar occlusion: combined local fibrinolysis and intravenous abciximab in acute vertebrobasilar stroke treatment (FAST): results of a multicenter study.
Eckert B; Koch C; Thomalla G; Kucinski T; Grzyska U; Roether J; Alfke K; Jansen O; Zeumer H
Stroke; 2005 Jun; 36(6):1160-5. PubMed ID: 15890988
[TBL] [Abstract][Full Text] [Related]
5. Sequential combination of intravenous recombinant tissue plasminogen activator and intra-arterial urokinase in acute ischemic stroke.
Lee KY; Kim DI; Kim SH; Lee SI; Chung HW; Shim YW; Kim SM; Heo JH
AJNR Am J Neuroradiol; 2004 Oct; 25(9):1470-5. PubMed ID: 15502123
[TBL] [Abstract][Full Text] [Related]
6. Intra-arterial reteplase and intravenous abciximab in patients with acute ischemic stroke: an open-label, dose-ranging, phase I study.
Qureshi AI; Harris-Lane P; Kirmani JF; Janjua N; Divani AA; Mohammad YM; Suarez JI; Montgomery MO
Neurosurgery; 2006 Oct; 59(4):789-96; discussion 796-7. PubMed ID: 16915119
[TBL] [Abstract][Full Text] [Related]
7. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial.
Topol EJ;
Lancet; 2001 Jun; 357(9272):1905-14. PubMed ID: 11425410
[TBL] [Abstract][Full Text] [Related]
8. Thrombin generation and fibrinolytic activities among patients receiving reduced-dose alteplase plus abciximab or undergoing direct angioplasty plus abciximab for acute myocardial infarction.
Mak KH; Lee LH; Wong A; Chan C; Koh TH; Lau KW; Lim YL
Am J Cardiol; 2002 Apr; 89(8):930-6. PubMed ID: 11950430
[TBL] [Abstract][Full Text] [Related]
9. Abciximab as an adjunct to high-risk carotid or vertebrobasilar angioplasty: preliminary experience.
Qureshi AI; Suri MF; Khan J; Fessler RD; Guterman LR; Hopkins LN
Neurosurgery; 2000 Jun; 46(6):1316-24; discussion 1324-5. PubMed ID: 10834637
[TBL] [Abstract][Full Text] [Related]
10. Combined glycoprotein IIb/IIIa receptor inhibition and low-dose fibrinolysis for peripheral arterial thrombosis.
Rocha-Singh KJ; Trokey J
Catheter Cardiovasc Interv; 2002 Apr; 55(4):457-60. PubMed ID: 11948891
[TBL] [Abstract][Full Text] [Related]
11. Incomplete resolution of basilar artery occlusion after intra-arterial thrombolysis: abciximab and heparin prevent early rethrombosis.
Küker W; Friese S; Vogel W; Schmidt F; Weller M
Cerebrovasc Dis; 2000; 10(6):484-6. PubMed ID: 11070384
[No Abstract] [Full Text] [Related]
12. Clinical and radiological predictors of recanalisation and outcome of 40 patients with acute basilar artery occlusion treated with intra-arterial thrombolysis.
Arnold M; Nedeltchev K; Schroth G; Baumgartner RW; Remonda L; Loher TJ; Stepper F; Sturzenegger M; Schuknecht B; Mattle HP
J Neurol Neurosurg Psychiatry; 2004 Jun; 75(6):857-62. PubMed ID: 15146000
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction.
Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators
Lancet; 2001 Aug; 358(9282):605-13. PubMed ID: 11530146
[TBL] [Abstract][Full Text] [Related]
14. Clot lysis in a primate model of peripheral arterial occlusive disease with use of systemic or intraarterial reteplase: addition of abciximab results in improved vessel reperfusion.
Nakada MT; Montgomery MO; Nedelman MA; Guerrero JL; Cohen SA; Barnathan ES; Jordan RE
J Vasc Interv Radiol; 2004 Feb; 15(2 Pt 1):169-76. PubMed ID: 14963184
[TBL] [Abstract][Full Text] [Related]
15. High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (thrombolysis in myocardial infarction) 14.
Coulter SA; Cannon CP; Ault KA; Antman EM; Van de Werf F; Adgey AA; Gibson CM; Giugliano RP; Mascelli MA; Scherer J; Barnathan ES; Braunwald E; Kleiman NS
Circulation; 2000 Jun; 101(23):2690-5. PubMed ID: 10851205
[TBL] [Abstract][Full Text] [Related]
16. Reteplase monotherapy and reteplase/abciximab combination therapy in peripheral arterial occlusive disease: results from the RELAX trial.
Ouriel K; Castaneda F; McNamara T; Swischuk J; Tepe G; Smith JJ; Clark J; Duda S
J Vasc Interv Radiol; 2004 Mar; 15(3):229-38. PubMed ID: 15028807
[TBL] [Abstract][Full Text] [Related]
17. Emergent carotid stenting and intra-arterial abciximab in acute ischemic stroke due to tandem occlusion.
Al-Mufti F; Amuluru K; Manning NW; Khan I; Peeling L; Gandhi CD; Prestigiacomo CJ; Pushchinska G; Fiorella D; Woo HH
Br J Neurosurg; 2017 Oct; 31(5):573-579. PubMed ID: 28298139
[TBL] [Abstract][Full Text] [Related]
18. Intraarterial reteplase and intravenous abciximab for treatment of acute ischemic stroke. A preliminary feasibility and safety study in a non-human primate model.
Qureshi AI; Suri MF; Ali Z; Ringer AJ; Boulos AS; Nakada MT; Alberico RA; Martin LB; Guterman LR; Hopkins LN
Neuroradiology; 2005 Nov; 47(11):845-54. PubMed ID: 16205896
[TBL] [Abstract][Full Text] [Related]
19. Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial.
Lincoff AM; Califf RM; Van de Werf F; Willerson JT; White HD; Armstrong PW; Guetta V; Gibler WB; Hochman JS; Bode C; Vahanian A; Steg PG; Ardissino D; Savonitto S; Bar F; Sadowski Z; Betriu A; Booth JE; Wolski K; Waller M; Topol EJ;
JAMA; 2002 Nov; 288(17):2130-5. PubMed ID: 12413372
[TBL] [Abstract][Full Text] [Related]
20. Thrombus formation during intracranial aneurysm coil placement: treatment with intra-arterial abciximab.
Song JK; Niimi Y; Fernandez PM; Brisman JL; Buciuc R; Kupersmith MJ; Berenstein A
AJNR Am J Neuroradiol; 2004 Aug; 25(7):1147-53. PubMed ID: 15313699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
